Non-penetrating glaucoma surgery using AquaFlow(TM) collagen implants

Demeter S, Hailey D
Record ID 32001000978
English, French
Authors' objectives:

To summarise the available evidence on the use of AquaFlow(TM) collagen implants in non-penetrating glaucoma surgery.

Authors' recomendations: - AquaFlow(TM) is an absorbable collagen implant for use in non-penetrating surgery for primary open angle glaucoma. Its purpose is to facilitate drainage of fluid from the eye, thereby reducing intraocular pressure. - AquaFlow(TM) is approved for use in Canada in medically refractory cases of primary open angle glaucoma. - Non-penetrating glaucoma surgery with the AquaFlow(TM) implant appears to be a relatively safe procedure. However, there is a steep learning curve for the surgeon and it is initially associated with a high rate of conversion to conventional surgery during the operation. - Limited evidence from small non-randomized trials suggests that the AquaFlow(TM) implant may offer benefits over conventional surgical approaches in terms of reduced complication rates, reduced medication use, an earlier return of improved vision and sustained control of intraocular pressure. However, the efficacy and cost-effectiveness of this approach have not been established.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Glaucoma Drainage Implants
  • Glaucoma
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.